Type 2 Diabetes Treated With Insulin Clinical Trial
— In-FIOfficial title:
Comparison of Postprandial Glycemic Control in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus Using Novolog vs. Fiasp Insulin: a Randomized Controlled Open Label Trial
Verified date | February 2024 |
Source | Boston Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Hyperglycemia affects 30-40% of hospitalized patients. Despite the fact that basal/bolus insulin therapy has been demonstrated to improve glycemic control and clinical outcomes in patients, achieving good glucose control remains a challenge. This study examines the effects of Fiasp (a faster acting insulin) on blood sugars after meals compared to another type of insulin known as Novolog. The study will be performed in patients with type 2 diabetes admitted to the hospital, who are not in the intensive care unit, and who are being seen by the inpatient diabetes consult team. Eligible participants will be treated with Fiasp or Novolog injected multiple times a day before meals and at bedtime, in addition to a once daily injection of insulin glargine as basal insulin. Which type of meal time insulin (Fiasp vs Novolog) the subject gets is decided by chance, like the flip of a coin. Insulin doses will be started and titrated based on a protocol. All the subjects will wear a blinded continuous glucose monitoring (CGM)) sensor placed in their arm which they will wear for 72 hours during the study. The glucose values from the CGM, collected during the time it is worn, will be downloaded and compared to assess the response to the two different types of insulins - Fiasp and Novolog. The goal is to determine if Fiasp works as well as or better than Novolog in controlling blood sugars, particularly after meals, in the subjects of the study.
Status | Completed |
Enrollment | 137 |
Est. completion date | May 27, 2023 |
Est. primary completion date | May 27, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 80 Years |
Eligibility | Inclusion criteria 1. English-speaking 2. Males and female adult subjects admitted to Boston Medical Center to a medical or surgical floor. 3. Consultation by the Inpatient Diabetes Service at Boston Medical Center is required prior to consent. 4. Age = 21 and <= 80 years. 5. Diagnosed with type 2 diabetes at least 180 days prior to screening. 6. Hyperglycemia during admission, as defined by a point of care and/or venous blood glucose = 140 mg/dL. 7. Prior to admission subjects must be using one of the following for outpatient diabetes management: 1. Insulin 2. = 2 oral/injectable agents 3. One oral/injectable agent with a hemoglobin A1c of = 8% within 3 months of enrollment. 8. Patients who are expected to remain hospitalized for a minimum of 48 hours following CGM sensor placement. 9. BMI <45 kg/m^2. 10. Subjects must have insulin glargine dosing planned at bedtime for the duration of the study period. Morning and afternoon dosing of insulin glargine are exclusionary. Exclusion criteria: 1. Patients with a history of type 1 diabetes or late-onset autoimmune diabetes (LADA). 2. Treatment or plan for treatment with glucocorticoids during the index hospitalization. 3. Female patients who are pregnant (tested during hospitalization or screening) or breast-feeding during the hospitalization. 4. Patients admitted with the following conditions: diabetic ketoacidosis, hyperosmolar hyperglycemic state, solid organ transplantation, or coronary artery bypass surgery. 5. Prior diagnosis of gastroparesis or cirrhosis. 6. Acute or chronic kidney disease with a serum creatinine of = 2 mg/dL at the time of screening. 7. Clinically significant nausea and/or vomiting or unable to consume more than 30 grams of carbohydrate at each meal. 8. Patients expected to receive nothing by mouth (NPO) for >24 hours. 9. Use of continuous or intermittent enteral feeding or parenteral nutrition. 10. Patient receiving aspirin and/or vitamin C during the hospitalization. 11. Any mental condition rendering the subject unable to provide informed consent. 12. Patients currently incarcerated. 13. Patients using >1 unit/kg/day of insulin prior to admission. 14. Insulin pump usage within the 2 weeks prior to or during admission. 15. Patients currently using real-time continuous glucose monitoring (CGM) or personal flash glucose monitoring system (FGM). 16. Patients with a history of an allergy to any of the types of insulin or one of the excipients in the insulin used in the study. |
Country | Name | City | State |
---|---|---|---|
United States | Boston Medical Center | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Boston Medical Center | Novo Nordisk A/S |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Postprandial Glucose Control | Percent of time spent in the glycemic target range of 100-180 mg/dL in the 4 hour postprandial period will be assessed using a continuous glucose monitoring (CGM) system. | 3 days | |
Secondary | Glycemic Control While Hospitalized | Percent of time spent in the glycemic target range of 100-180 mg/dL during the duration of the study will be assessed using a continuous glucose monitoring (CGM) system. | 3 days | |
Secondary | Percent of Time Spent in Glycemic Range of 70-140 mg/dL | Percent of time spent in the glycemic target range of 70-140 mg/dL during the duration of the study assessed using a continuous glucose monitoring (CGM) system. | 3 days | |
Secondary | Percent of Time Spent With Hypoglycemia During Hospitalization | The percent of time in three categories of hypoglycemia : <70 mg/dL, <54 mg/dL, and <40 mg/dL will be assessed using a CGM during hospitalization. | 3 days | |
Secondary | Percent of Nocturnal Time in Glycemic Target Range 100-180 mg/dL | The percent of nocturnal time (from 00.01 AM to 5:59 AM) in the glycemic target range of 100-180 mg/dL | 3 days | |
Secondary | Percent of Nocturnal Time Spent With Hypoglycemia | The percent of nocturnal time (from 00.01 AM to 5:59 AM) in three categories of hypoglycemia: <70 mg/dL, <54 mg/dL, and <40 mg/dL will be assessed using CGM. | 3 days | |
Secondary | Percent of Postprandial Time Spent With Level 1 Hyperglycemia | The percent of time spent in level 1 hyperglycemia (181-239 mg/dL) will be assessed using CGM in the 4 hour postprandial period. | 4 hours postprandial | |
Secondary | Percent of Postprandial Time Spent With Level 2 Hyperglycemia | The percent of time spent in level 2 hyperglycemia (>240 mg/dL) will be assessed using CGM in the 4 hour postprandial period. | 4 hours postprandial | |
Secondary | Percent of Postprandial Time Spent With Hypoglycemia | The percent of postprandial time in three categories of hypoglycemia will be assessed: <70 mg/dL, <54 mg/dL, and <40 mg/dL. | 4 hours postprandial |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04522882 -
Clinical Data Collection for the Closed Loop Development for the Type 2 Diabetes Treatment - DT2_1
|
N/A | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Not yet recruiting |
NCT05185518 -
Assessment of an Integrated Continuous Glucose Monitor and Insulin Injection Port in Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05893797 -
A Study of LY8888AX in Participants Using a Connected Insulin Management Platform
|
N/A | |
Completed |
NCT02791295 -
Lifestyle Intervention in Type 2 Diabetes
|
N/A | |
Withdrawn |
NCT04957173 -
Intensive Lifestyle Intervention in Patients With Insulin-treated Type 2 Diabetes: a Pilot Project
|
N/A | |
Not yet recruiting |
NCT05317585 -
Continuous Glucose Monitor Use in Pregnancy
|
N/A | |
Completed |
NCT05372471 -
Efficacy of the Digital Platform for Diabetes Care Compared to Usual Care in Patients Diagnosed With Type 2 Diabetes.
|
N/A | |
Completed |
NCT05111301 -
Control-IQ Technology in Individuals With Type 2 Diabetes
|
N/A | |
Active, not recruiting |
NCT04585191 -
Reducing Treatment Risk in Older Adults With Diabetes
|
N/A | |
Recruiting |
NCT04871438 -
Flash CONtinous Glucose Monitoring in TRansition to Outpatient: Libre for Type 2 Diabetes Mellitus (CONTROL-DM)
|
N/A | |
Completed |
NCT06060743 -
Examining the Effect of Mobile Application on Insulin Use Perception and Self-Management
|
N/A | |
Completed |
NCT04005261 -
C-peptide Concentrations in Type 2 Diabetes Treated With Insulin; is it Time to Revise the Treatment of Type 2 Diabetes
|
||
Terminated |
NCT03980236 -
Feasibility of Using the Livongo-Insulia Study App for Patients With Type 2 Diabetes [Pilot Study]
|
N/A | |
Not yet recruiting |
NCT06185296 -
The Intelligent Diabetes TelemonitoRing Using Decision Support to Treat Patients on Insulin Therapy
|
N/A | |
Completed |
NCT03437525 -
Peer Support in Diabetes Management - Insulin Peer Support
|
N/A | |
Active, not recruiting |
NCT03070106 -
Diabetes: Functional Medicine Approach vs. Usual Care
|
N/A | |
Completed |
NCT02060916 -
Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT05785832 -
A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04945070 -
INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi
|
Phase 4 |